Literature DB >> 26617756

Expression of p53β and Δ133p53 isoforms in different gastric tissues.

Wansheng Ji1, Na Zhang2, Hongmei Zhang1, Jingrong Ma2, Hua Zhong1, Jianxin Jiao1, Zhixing Gao1.   

Abstract

This study aims to detect the mRNA of p53β and Δ133p53 isoforms in three gastric carcinoma cell lines and tissues of superficial gastritis, atrophic gastritis, gastric carcinoma, or paracancerous area. Nested reverse transcription PCR was used to detect the mRNA of p53β and Δ133p53 isoforms in tissues of superficial gastritis, chronic atrophic gastritis, gastric cancer cell lines (SGC-7901, MKN45, KATO III), gastric adenocarcinoma, and paracancerous lesion. The amplified products were shown by agarose gel electrophoresis. The expression difference among various tissues was analyzed by x(2) tests. The positive rates of ∆133p53 mRNA were 73.3% (11/15) in gastric adenocarcinoma and 20% (3/15) in paracancerous tissue, whereas the positive rates of p53β mRNA were 20% (3/15) in gastric adenocarcinoma and 66.7% (10/15) in paracancerous tissue. The difference between adenocarcinoma and paracancerous tissues was significant (P<0.05). The positive rates of ∆133p53 mRNA were 25% (5/20), 50% (15/30), and 75% (15/20), respectively, in superficial gastritis, atrophic gastritis, and gastric adenocarcinoma; the positive rates of p53β mRNA were 65% (13/20), 33.3% (10/30), and 25% (5/20), respectively, in superficial gastritis, atrophic gastritis, and gastric adenocarcinoma. The difference between adenocarcinoma and superficial gastritis samples was significant (P<0.05). Both p53β and ∆133p53 mRNAs were positive in MKN45; only p53β mRNA was detected in SGC7901; neither p53β nor ∆133p53 mRNA was detected in KATO III. ∆133p53 and p53β, which are possible indicators for the diagnosis and biological therapy of gastric carcinoma, were expressed differentially in different gastric tissues.

Entities:  

Keywords:  Gastric carcinoma; isoforms; p53; p53β; Δ133p53

Mesh:

Substances:

Year:  2015        PMID: 26617756      PMCID: PMC4637571     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Influenza A viruses control expression of proviral human p53 isoforms p53β and Delta133p53α.

Authors:  Olivier Terrier; Virginie Marcel; Gaëlle Cartet; David P Lane; Bruno Lina; Manuel Rosa-Calatrava; Jean-Christophe Bourdon
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Differential forms of p53 in medulloblastoma primary tumors, cell lines and xenografts.

Authors:  Tzvetomira Philipova; Ninib Baryawno; Wolfgang Hartmann; Torsten Pietsch; Henrik Druid; John Inge Johnsen; Tomas J Ekström
Journal:  Int J Oncol       Date:  2010-12-23       Impact factor: 5.650

3.  Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53.

Authors:  Vilma Graupner; Klaus Schulze-Osthoff; Frank Essmann; Reiner U Jänicke
Journal:  Cell Cycle       Date:  2009-04-23       Impact factor: 4.534

Review 4.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

5.  The p53 Isoform Deltap53 lacks intrinsic transcriptional activity and reveals the critical role of nuclear import in dominant-negative activity.

Authors:  Wan Mui Chan; Randy Y C Poon
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

Review 6.  Mdm2-mediated ubiquitylation: p53 and beyond.

Authors:  J-C Marine; G Lozano
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

7.  Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

Authors:  Hanna Berglind; Yudi Pawitan; Shunsuke Kato; Chikashi Ishioka; Thierry Soussi
Journal:  Cancer Biol Ther       Date:  2008-05-11       Impact factor: 4.742

8.  Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.

Authors:  N Ånensen; S M Hjelle; W Van Belle; I Haaland; E Silden; J-C Bourdon; R Hovland; K Taskén; S Knappskog; P E Lønning; Ø Bruserud; B T Gjertsen
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

9.  Expression of p53 isoforms in squamous cell carcinoma of the head and neck.

Authors:  Linda Boldrup; Jean-Christophe Bourdon; Philip J Coates; Björn Sjöström; Karin Nylander
Journal:  Eur J Cancer       Date:  2007-01-09       Impact factor: 9.162

10.  Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Authors:  G Hofstetter; A Berger; E Schuster; A Wolf; G Hager; I Vergote; I Cadron; J Sehouli; E I Braicu; S Mahner; P Speiser; C Marth; A G Zeimet; H Ulmer; R Zeillinger; N Concin
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

View more
  5 in total

Review 1.  A mouse model of the Δ133p53 isoform: roles in cancer progression and inflammation.

Authors:  Marina Kazantseva; Sunali Mehta; Ramona A Eiholzer; Noelyn Hung; Anna Wiles; Tania L Slatter; Antony W Braithwaite
Journal:  Mamm Genome       Date:  2018-07-10       Impact factor: 2.957

2.  Role of Δ133p53 isoform in NF-κB inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells.

Authors:  Hong-Mei Zhang; Xiao-Guang Sang; Yan-Ze Wang; Can Cui; Li Zhang; Wan-Sheng Ji
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

3.  High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

Authors:  Katharina Bischof; Stian Knappskog; Ingunn Stefansson; Emmet Martin McCormack; Jone Trovik; Henrica Maria Johanna Werner; Kathrine Woie; Bjorn Tore Gjertsen; Line Bjorge
Journal:  BMC Cancer       Date:  2018-06-25       Impact factor: 4.430

Review 4.  Adaptive homeostasis and the p53 isoform network.

Authors:  Sunali Mehta; Hamish Campbell; Catherine J Drummond; Kunyu Li; Kaisha Murray; Tania Slatter; Jean-Christophe Bourdon; Antony W Braithwaite
Journal:  EMBO Rep       Date:  2021-11-15       Impact factor: 8.807

5.  A functional interplay between Δ133p53 and ΔNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation.

Authors:  Lu Gong; Xiao Pan; Chuan-Bian Lim; Anna de Polo; John B Little; Zhi-Min Yuan
Journal:  Oncogene       Date:  2018-01-26       Impact factor: 9.867

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.